Back to overview

3-year Industrial Postdoc Fellowship awarded to Lluís Riera-Ponsatí

This grant from the Innovation Fund Denmark (IFD) will help us in further establishing our drug discovery pipeline, aimed at developing disease-modifying RNA Therapies for Parkinson's Disease at NEUmiRNA, in collaboration with Aalborg University and the Center for RNA Medicine (CRM).
Development
17.9.2025
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer
We are excited to announce that Ellen K. Donnelly, Ph.D. has been appointed Chief Executive Officer of Neumirna Therapeutics.
Read full article
Development
8.7.2025
Neumirna Appoints Ina Brünig-Traebert as Chief Development Officer
With a proven track record in RNA therapies, Ina will guide Neumirna’s transition into clinical-stage development.
Read full article
Funding
Awards
12.6.2025
Neumirna Receives 2024 CURE Epilepsy Catalyst Award
$250,000 in funding to support biomarker research and development of RNA therapy for drug-resistant epilepsy
Read full article